case_images: PMC8288029_01
case_images: On December 17, 2020, the whole abdominal enhanced CT in our hospital showed a large number of peritoneal effusion, multiple metastases of omentum and mesentery (A, B), liver II metastases (C, red arrow) and V metastases (D, yellow arrow).
case_images: fonc-11-688231-g001.jpg
case_images: PMC8288029_01_fonc-11-688231-g001.jpg
case_images: f1
case_images: On December 17, 2020, the whole abdominal enhanced CT in our hospital showed liver II and V metastases considered, a large number of peritoneal effusion, and multiple metastases of omentum and mesentery ( Figure 1 ).
case_images: (A, B) The severe rashes after receiving fruquintinib for approximately 2 weeks.
case_images: fonc-11-688231-g002.jpg
case_images: PMC8288029_01_fonc-11-688231-g002.jpg
case_images: f2
case_images: On January 12, 2021, the patient developed severe rashes after receiving fruquintinib (3 mg qd) for approximately 2 weeks ( Figures 2A, B ).
case_images: The case timeline.
case_images: fonc-11-688231-g003.jpg
case_images: PMC8288029_01_fonc-11-688231-g003.jpg
case_images: f3
case_images: The case timeline is presented in  Figure 3 .